In its first major deal, Merrimack Pharmaceuticals Inc. has granted rights to its monoclonal antibody MM-121 to Paris-based drug and vaccine maker Sanofi-Aventis Group SA in exchange for $60 million up front and a potential $470 million in milestones. (BioWorld Today)
